WO2005082353A3 - Use of beta-lapachone for treating or preventing cancer - Google Patents

Use of beta-lapachone for treating or preventing cancer Download PDF

Info

Publication number
WO2005082353A3
WO2005082353A3 PCT/US2005/005354 US2005005354W WO2005082353A3 WO 2005082353 A3 WO2005082353 A3 WO 2005082353A3 US 2005005354 W US2005005354 W US 2005005354W WO 2005082353 A3 WO2005082353 A3 WO 2005082353A3
Authority
WO
WIPO (PCT)
Prior art keywords
lapachone
beta
treating
preventing cancer
present
Prior art date
Application number
PCT/US2005/005354
Other languages
French (fr)
Other versions
WO2005082353A2 (en
Inventor
Chiang Li
Original Assignee
Arqule Inc
Chiang Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/846,980 external-priority patent/US20050187288A1/en
Application filed by Arqule Inc, Chiang Li filed Critical Arqule Inc
Priority to EP05723361A priority Critical patent/EP1727537A2/en
Priority to CA002556758A priority patent/CA2556758A1/en
Priority to JP2006554258A priority patent/JP2007523187A/en
Publication of WO2005082353A2 publication Critical patent/WO2005082353A2/en
Publication of WO2005082353A3 publication Critical patent/WO2005082353A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides for methods that utilize agents effective in the treatment of cancerous and pre-cancerous conditions. Moreover, the present invention provides agents capable of acting as an inhibitor of cell proliferation.
PCT/US2005/005354 2004-02-20 2005-02-16 Use of beta-lapachone for treating or preventing cancer WO2005082353A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05723361A EP1727537A2 (en) 2004-02-20 2005-02-16 Use of beta-lapachone for treating or preventing cancer
CA002556758A CA2556758A1 (en) 2004-02-20 2005-02-16 Use of beta-lapachone for treating or preventing cancer
JP2006554258A JP2007523187A (en) 2004-02-20 2005-02-16 Use of β-lapachone for treating or preventing cancer

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US54591704P 2004-02-20 2004-02-20
US54591604P 2004-02-20 2004-02-20
US54591504P 2004-02-20 2004-02-20
US54598004P 2004-02-20 2004-02-20
US54591404P 2004-02-20 2004-02-20
US54595004P 2004-02-20 2004-02-20
US60/545,915 2004-02-20
US60/545,914 2004-02-20
US60/545,916 2004-02-20
US60/545,917 2004-02-20
US60/545,950 2004-02-20
US10/846,980 2004-05-14
US10/846,980 US20050187288A1 (en) 2004-02-20 2004-05-14 Beta-lapachone and methods of treating cancer

Publications (2)

Publication Number Publication Date
WO2005082353A2 WO2005082353A2 (en) 2005-09-09
WO2005082353A3 true WO2005082353A3 (en) 2005-11-17

Family

ID=34916680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005354 WO2005082353A2 (en) 2004-02-20 2005-02-16 Use of beta-lapachone for treating or preventing cancer

Country Status (1)

Country Link
WO (1) WO2005082353A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN105073781A (en) 2013-01-11 2015-11-18 加州生物医学研究所 Bovine fusion antibodies
WO2014134202A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
WO2002058694A2 (en) * 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US20030036515A1 (en) * 2000-11-07 2003-02-20 Pardee Arthur B. Method of treating hematologic tumors and cancers
US20040001871A1 (en) * 2002-04-23 2004-01-01 David Boothman Lapachone delivery systems, compositions and uses related thereto
WO2004045557A2 (en) * 2002-11-18 2004-06-03 Arqule, Inc. Novel lapachone compounds and methods of use thereof
WO2004050033A2 (en) * 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
WO2002058694A2 (en) * 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers using beta lapachone
US20030036515A1 (en) * 2000-11-07 2003-02-20 Pardee Arthur B. Method of treating hematologic tumors and cancers
US20040001871A1 (en) * 2002-04-23 2004-01-01 David Boothman Lapachone delivery systems, compositions and uses related thereto
WO2004045557A2 (en) * 2002-11-18 2004-06-03 Arqule, Inc. Novel lapachone compounds and methods of use thereof
WO2004050033A2 (en) * 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAU, YAT-PANG ET AL: "Involvement of hydrogen peroxide in topoisomerase inhibitor .beta.-lapachone-induced apoptosis and differentiation in human leukemia cells", FREE RADICAL BIOLOGY & MEDICINE , 24(4), 660-670 CODEN: FRBMEH; ISSN: 0891-5849, 1998, XP008047537 *
DUBIN, MARTA ET AL: "Cytotoxicity of .beta.-lapachone, an o-naphthoquinone with possible therapeutic uses", MEDICINA (BUENOS AIRES, ARGENTINA) , 61(3), 343-350 CODEN: MEDCAD; ISSN: 0025-7680, 2001, XP008047526 *
PLANCHON S M ET AL: "BCL-2 PROTECTS AGAINST BETA-LAPACHONE-MEDIATED CASPASE 3 ACTIVATIONAND APOPTOSIS IN HUMAN MYELOID LEUKEMIA (HL-60) CELLS", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 6, no. 3, 1999, pages 485 - 492, XP000957471, ISSN: 1021-335X *
PLANCHON S M ET AL: "BETA-LAPACHONE-MEDIATED APOPTOSIS IN HUMAN PROMYELOCYTIC LEUKEMIA (HL-60) AND HUMAN PROSTATE CANCER CELLS: A P53-INDEPENDENT RESPONSE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 17, 1 September 1995 (1995-09-01), pages 3706 - 3711, XP000611541, ISSN: 0008-5472 *
REINICKE K E ET AL: "DEVELOPMENT OF BETA-LAPACHONE PRODRUGS FOR THERAPY AGAINST HUMAN CANCER CELLS WITH ELEVATED NAD(P)H:QUINONE OXIDOREDUCTASE 1 LEVELS", CLINICAL CANCER RESEARCH, THE ASSOCIATION, DENVILLE, NJ, US, vol. 11, no. 8, 15 April 2005 (2005-04-15), pages 3055 - 3064, XP008046994, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2005082353A2 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
WO2004034990A3 (en) Methods and compositions for use in treating cancer
WO2004030625A3 (en) Synergistic methods and compositions for treating cancer
WO2007061874A3 (en) Methods and compositions for use in treating cancer
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2006015263A3 (en) Lonidamine analogs
WO2009064444A9 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2007011962A3 (en) Treatment of cancer
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2007129226A3 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
AU2003237367A1 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
RS20050945A (en) Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
WO2005110479A3 (en) Treatments for pancreatic cancer
EP1774043A4 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2006093813A3 (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
WO2006069253A3 (en) Trefoil factors and methods of treating proliferation disorders using same
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2008054711A3 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2006015191A3 (en) Multicyclic lonidamine analogs
WO2006091965A3 (en) Nod1 as an anti-tumor agent
WO2005082357A8 (en) Use of beta-lapachone for treating hematologic tumors
WO2007076320A8 (en) Compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2556758

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006554258

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005723361

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005723361

Country of ref document: EP